{"id":3093,"date":"2022-02-28T10:46:34","date_gmt":"2022-02-28T00:46:34","guid":{"rendered":"\/eu-uk\/?p=3093"},"modified":"2022-02-28T10:46:34","modified_gmt":"2022-02-28T00:46:34","slug":"striate-market-update","status":"publish","type":"post","link":"\/eu-uk\/blog\/2022\/02\/28\/striate-market-update\/","title":{"rendered":"Striate+\u2122 Market Update"},"content":{"rendered":"

Orthocell\u2019s Striate+\u2122 dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.<\/p>\n

The Company\u2019s strategy to engage key-opinion-leaders (KOLs) to drive product awareness and uptake of Striate+\u2122 in key global health markets is progressing well. Product sales of Striate+\u2122 from the US KOL\u2019s alone has reached over 1,500 units.<\/p>\n

Approvals are now in place to upgrade our Perth-based manufacturing facility with capacity to produce more than 100,000 units per annum. Commissioning of the manufacturing facility is expected in Q4 CY2022. A big win for Orthocell and Australia\u2019s biomanufacturing sector.<\/p>\n

Click here to read today\u2019s ASX release.<\/span><\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell\u2019s Striate+\u2122 dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.<\/p>\n","protected":false},"author":2,"featured_media":3094,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3093","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t